Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
18 sept. 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...